Our Recommendations
- Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV (2022)
- Guidelines for Diagnosing and Managing Disseminated Histoplasmosis among People Living with HIV (2020)
- Manual for male circumcision under local anaesthesia and HIV prevention services for adolescent boys and men (2018)
- Consolidated guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection (2016)
- Latent Tuberculosis Infection : Updated and consolidated guidelines for programmatic management (2018)
New Publications
- Algoritmos de diagnóstico y tratamiento para el control de las infecciones perinatales por VIH, sífilis, hepatitis B y Chagas (2024)
- A shot at ending AIDS — How new long-acting medicines could revolutionize the HIV response (2025)
- Preventing HIV misdiagnosis: implementation guide (2024)
- Dolutegravir Resistance in Malawi’s National HIV Treatment Program (2022)
- WFP Malawi Country Brief, April 2022 (2022)
Filter
346
Featured
Recommendations
13
New Publications
33
Language
Document type
No document type
119
Guidelines
117
Studies & Reports
63
Fact sheets
22
Infographics
9
Manuals
5
Situation Updates
3
Training Material
2
Resource Platforms
2
Strategic & Response Plan
2
Brochures
1
Online Courses
1
Countries / Regions
Malawi
8
Global
7
Latin America and the Carribbean
7
South Africa
7
Africa
5
East and Southern Africa
5
Uganda
4
Asia
3
South–East Asia Region
3
Western and Central Europe
3
Kenya
2
Lesotho
2
Zambia
2
Nepal
1
El Salvador
1
Syria
1
Laos
1
Afghanistan
1
Zimbabwe
1
Philippines
1
Mozambique
1
USA
1
Cambodia
1
Guinea-Bissau
1
Congo, Democratic Republic of
1
Middle East and North Africa
1
Western Pacific Region
1
North America
1
Jamaica
1
Argentina
1
Bangladesh
1
Vietnam
1
Brazil
1
Sri Lanka
1
Russia
1
Yemen
1
Angola
1
Bhutan
1
India
1
Pakistan
1
Authors & Publishers
Publication Years
Category
Clinical Guidelines
52
Countries
30
Women & Child Health
7
Pharmacy & Technologies
3
Public Health
2
Capacity Building
1
Key Resources
1
MEDBOX Issue Brief no.18.
The MEDBOX team has compiled a new issue brief on the impact of COVID-19 on PLHIV HIV prevention programmes and treatment for this year's World AIDS Day on 1 December 2021.
Validation of elimination of mother-to-child transmission, or vertical transmission, of HIV, syphilis and hepatitis B virus (HBV), is an attestation that a country has successfully met standard criteria for elimination, or for being at 1 of the 3 levels of achievement on the ‘Path to Elimination...
En El Salvador, desde el surgimiento del primer caso de infección por Virus de Inmunodeficiencia Humana (VIH), la consejería de VIH se constituye en un recurso que favorece la prevención, encaminada a la identificación de factores de riesgo para ITS/VIH y otras Infecciones de Transmisión Sexual...
UNAIDS and the World Health Organization have published this updated guidance on ethical considerations in HIV prevention trials. The new guidance is the result of a year-long process that saw more than 80 experts and members of the public give inputs and is published 21 years after the first editio...
PEPFAR Malawi’s Country Operational Plan (COP) 2021 reflects a culmination of strong interagency collaboration between the PEPFAR Malawi team, Government of Malawi (GoM), and civil society organizations (CSOs) to mitigate the devastating impacts of COVID-19 and sustain progress achieved over the l...
1 July 2021; Report shows big COVID-19-related HIV prevention programme service disruptions, but highlights that HIV service innovations and adaptations are possible.
A synthesis report on programme disruptions and adaptations during the COVID-19 pandemic in 2020
This technical note summarizes the consolidated guidelines and adapts them to the context of Latin America and the Caribbean, in order to adequately monitor the number of people on ART. For this purpose, guidance is presented on the indicators and the methodology to know more precisely the number of...
25 February 2021
This technical guidance is a living document that builds on guidelines and reports of the UNAIDS Joint Programme. The definitions contained herein are working definitions that are subject to change. Updates will also be added further to the work of the multistakeholder Task Team on...
E-Learning for front-line managers on COVID-19 response to vulnerable populations (24 languages)
recommended
This e-learning course is designed for front-line managers of institutions hosting or serving people who are medially or socially vulnerable to the impact of COVID-19. It is a non-moderated and self-paced course. You can decide when to start it, interrupt and resume to continue at any time. In total...
15 July 2021. This report describes the demographics, clinical presentation, clinical outcomes, and risk factors among people living with HIV (PLHIV) who have been hospitalized for suspected or confirmed COVID-19.
The specific objectives of the analysis were to:
describe the clinical char...
Resource Page for People At Risk For or With HIV and for Clinicians
12 January 2021
The COVID-19 vaccines under development or approved by regulators are believed to be safe for most people, including people living with HIV.
Slideset updated regularly to include the latest data and guidance on COVID-19 risk and management in special populations, including children and pregnant women, and persons with comorbidities.
To assess the impact of the COVID-19 pandemic on health and HIV expenditure, UNAIDS carried out a modelling study on fiscal space for health and HIV. From a sample of 28 countries, three countries—the Democratic Republic of the Congo, Jamaica, and Lesotho—were selected to capture health and HIV ...
Development of one or more vaccines for Neisseria gonorrhoeae is an important objective for sexual and reproductive health worldwide, and for the fight against antimicrobial resistance.
WHO preferred product characteristics (PPCs) provide strategic guidance as to WHO’s preferences for new vacci...
12 January 2021
The COVID-19 vaccines under development or approved by regulators are believed to be safe for most people, including people living with HIV.
The HIV drug resistance report 2021 summarizes findings from 38 countries that had finalized the surveys by the time of this report and shared data with WHO.
Pretreatment HIVDR to non-nucleoside reverse-transcriptase inhibitors (NNRTI) can affect more than 10% of adults starting therapy and is fo...
This document synthesizes key elements of the World Health Organization (WHO) normative guidance on health policy and system support for community health worker (CHW) programmes and their application for HIV programmes. Building on relevant elements of HIV guidelines, tools and evidence identified b...
12 January 2021
The COVID-19 vaccines under development or approved by regulators are believed to be safe for most people, including people living with HIV.
This document is also available in Arabic and Portuguese.
